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Abstract 
Cholesterol ester storage disease (CESD) is a rare autosomal recessive lipid storage 
disorder associated with mutations of the gene encoding lysosomal acid lipase, 
manifestations of which include chronic liver disease and early atherosclerosis.  Although 
normally presenting in childhood, severity is variable and the condition can occasionally 
remain undetected until middle age.  Typical presentation is with asymptomatic 
hepatosplenomegaly and hyperlipidemia, and the condition is probably underdiagnosed.  
Treatment is supportive and may include attention to cardiovascular risk factors.  Phase I/II 
trials of enzyme replacement therapy are ongoing, but this approach remains experimental.  
We present the case of a 42 year-old woman diagnosed with CESD in childhood who ran an 
indolent course until re-presentation with cirrhotic hydrothorax.  She underwent orthotopic 
liver transplantation but required re-transplantation for hepatic artery thrombosis. She 
remains well with excellent graft function two years later.  Although atherosclerosis was 
apparent at assessment, and may have contributed to hepatic artery thrombosis, partial 
correction of the metabolic defect and restoration of liver function by transplantation 
together with ongoing medical therapy should permit reasonable survival over the longer 
term from both a liver and vascular perspective.  This is the first reported case of orthotopic 
liver transplantation for CESD in an adult, which was the only available option to improve 
survival.  The case highlights the importance of monitoring patients with CESD through 
adulthood and suggests that liver replacement at a later stage may yet be indicated and 
remains of benefit. 
 
Synopsis 
Regular follow up of liver function in adults with cholesterol ester storage disease, an 
uncommon lipid storage disorder, is an important consideration as orthotopic liver 
transplantation may be required to maintain long term survival.  
  
Introduction 
Cholesterol ester storage disease (CESD) is a rare autosomal recessive lipid storage 
disorder caused by lysosomal acid lipase (LAL) deficiency; this results in chronic 
liver disease. LAL is responsible for lysosomal cleavage of ester bonds in a range of 
lipids, including cholesterol esters and triglycerides. Thus, lack of LAL activity leads 
to intra-lysosomal accumulation of lipid (Anderson et al 1993). In humans, LAL is 
encoded by the LIPA gene located on chromosome 10. Complete loss-of-function 
mutations in LIPA lead to development of Wolman’s disease; this presents in infancy 
with failure to thrive and is usually fatal before the age of six months (Anderson and 
Sando 1991). CESD arises from hypomorphic mutations in the LIPA gene, which 
impair either expression or function of LAL. The majority of patients described to 
date possess a homozygous G to A substitution at location -1 of the splice donor site 
of exon 8 of LIPA (c.894G>A), which causes deletion of exon 8 and production of 
only 2-4% normal enzyme (Muntoni et al 2007). Heterozygote carrier frequencies 
have been estimated at 1 in 200 in northern Europe. However, genotypic 
heterogeneity is evident from reported compound heterozygotes with CESD 
(Muntoni et al 2007; Pisciotta et al 2009). 
 
CESD usually presents in childhood or adolescence with hypercholesterolemia or 
hepatomegaly due to hepatic steatosis that eventually progresses to cirrhosis 
(Chatrath et al 2009). Patients may succumb to complications relating to accelerated 
atherosclerosis or chronic liver disease, including hepatocellular carcinoma.  
Historically most patients known to have CESD died before the age of 30 years 
(Leone et al 1991; McCoy and Yokoyama 1991). However, it is increasingly 
  
recognised that milder forms of CESD can occur raising questions regarding the true 
natural history of this disorder. 
 
Case history 
A 42 year-old woman with a known history of CESD presented with a one-week 
history of progressive dyspnoea following administration of the H1N1 influenza 
vaccination. This was accompanied by more gradual abdominal distension.  The 
patient had originally come to medical attention at the age of 6 years with 
hepatosplenomegaly, whereby CESD was diagnosed following liver biopsy. She 
defaulted from follow-up and remained well into adulthood. At the age of 39 years, 
she sought further specialist review during pregnancy. Leukocyte acid esterase (i.e. 
leukocyte LAL) activity was low at 93 μmol/g/h (350–2000) with an elevated plasma 
chitotriosidase activity of 222 μmol/L/h (4–120), reaffirming the diagnosis. Lipid 
profile after overnight fasting demonstrated cholesterol 5.7 mmol/L, triglyceride 1.4 
mmol/L, HDL-C 0.93 mmol/L and LDL-C 4.17 mmol/L (Table 1). Pregnancy was 
uneventful and statin therapy was commenced post-partum. She defaulted from 
specialist follow-up, though continued statin therapy. 
 
No additional risk factors for chronic liver disease could be elicited at time of 
admission. Examination and chest radiography demonstrated the presence of a 
moderate right pleural effusion. Laboratory values were as follows: serum bilirubin 45 
μmol/L (< 17), prothrombin time (PT) 16.2 seconds (9.8–12.6), serum creatinine 57 
μmol/L (35–125), serum sodium 138 mmol/L (135–145), urine sodium <5 mmol/L. 
  
Her Model of End-stage Liver Disease score was 14 (Kamath et al., 2001), and 
United Kingdom End-stage Liver Disease (UKELD) score 50.1 (Lewsey et al., 2006). 
 
Pleural aspiration revealed a transudative effusion consistent with cirrhotic 
hydrothorax. Abdominal ultrasonography (US) demonstrated an enlarged nodular 
liver with patent portal and hepatic veins, gross ascites and 22 cm splenomegaly. 
Diuretics did not eliminate the requirement for regular thoracocentesis and a 
transjugular intrahepatic portosystemic shunt was felt unlikely to improve survival. 
Patients with end-stage liver disease and a UKELD score greater than 49 have 
previously been shown to benefit from liver transplantation in terms of their predicted 
survival at one year (Barber et al 2007), so this together with the patient’s diuretic 
resistant ascites lead us to proceed with a formal liver transplant assessment. 
 
Computed tomography (CT) confirmed the previous findings at US (Figure 1, panel 
A). Multiple high-density calcified nodules were also noted. Further, there was 
significant calcification of the descending aorta and aortic arch (Figure 1, panels B 
and C). Transthoracic echocardiography demonstrated mild left ventricular diastolic 
dysfunction but was otherwise normal; nine minutes of exercise treadmill testing 
were completed without electrocardiographic changes. Psychiatric evaluation was 
satisfactory and the patient was listed for liver transplantation on the grounds of the 
accepted indication of diuretic-resistant ascites in the form of hydrothorax, further 
supported by a UKELD score greater than 49.   
 
  
At operation, a mildly fatty, deceased donor allograft was implanted using duct-to-
duct biliary anastomosis and cavo-cavoplasty; an infra-renal aortic conduit was 
fashioned as initial arterial inflow was impaired. Cold and warm ischemic times were 
9 hours 10 minutes and 36 minutes, respectively. Standard post-operative 
immunosuppression with prednisolone, azathioprine and tacrolimus was 
administered.  Explant histology showed cirrhosis and was consistent with the 
diagnosis of CESD. Numerous lipid-laden macrophages and Kupffer cells were 
present within sinusoids that were CD68 positive and diastase periodic acid Schiff 
resistant (Figure 2). No additional form of chronic liver disease was apparent. 
 
Initial recovery post transplantation was complicated by an episode of acute cellular 
rejection that resolved with intravenous methyl-prednisolone and the patient was 
discharged home three weeks following transplantation. Repeat enzyme analysis at 
discharge showed normalisation of plasma chitotriosidase activity (42 μmol/L/h) and 
persistent leukocyte acid esterase deficiency (39 μmol/g/h). Repeated fasting lipid 
profile revealed a significant rise in HDL cholesterol (Table 1). 
 
Ten weeks post-transplant, during investigation for asymptomatic deranged liver 
function tests, imaging revealed unexpected hepatic artery thrombosis. Following 
clinical deterioration, the patient was subsequently re-listed and received a second 
transplant three months following her initial graft. Explant histology revealed an 
ischemic liver with organised thrombus of the hepatic artery at the hilum. The 
thrombosed arterial conduit was left in situ and not examined histologically. 
Subsequent progress has been uncomplicated; the patient was formally 
  
anticoagulated with low molecular weight heparin for three months following re-
transplant to reduce the risk of further hepatic artery thrombosis and is currently well 
on aspirin and statin therapy with excellent graft function almost two years following 
her second transplant.  
 
In order to further characterise this patient’s disorder, sequencing of LIPA was 
performed (Figure 3). This revealed compound heterozygosity: c.[894G>A];[599T>C] 
(the common c.894G>A substitution described above and a T to C substitution at 
location 599 causing leucine to proline substitution). The second mutation is thought 
to disrupt alpha helical structure (Anderson et al 1994). This compound 
heterozygous combination has been previously reported in siblings with CESD 
(Maslen et al 1995).  
 
Discussion 
We have presented the first report of adult liver transplantation for CESD. Our 
subject developed diuretic-resistant ascites with hydrothorax at the age of 42 years, 
having been diagnosed in childhood and run an indolent course during early 
adulthood.  CESD has been previously diagnosed de novo in adulthood:  Elleder et 
al (1990) described CESD in two women aged 43 and 56 years respectively, both of 
whom had asymptomatic hepatomegaly. One of these patients subsequently died of 
cerebrovascular disease.  The same group subsequently described a 51 year-old 
man with a long-standing history of dyslipidemia who died of cholangiocarcinoma 
(Elleder et al 2000). Autopsy findings demonstrated hepatomegaly with micronodular 
  
cirrhosis and disseminated cholangiocarcinoma; extensive severe atherosclerosis 
was also observed (Elleder et al 2000).  Chatrath et al (2009) reported a 43 year-old 
man diagnosed with CESD on liver biopsy performed with a view to staging hepatitis 
C infection.  Further, they summarised the features of an additional 18 cases 
previously described.  Reported deaths were either due to vascular disease or 
hepatic disease (liver failure or hepatobiliary malignancy). 
 
No drug therapy exists for this condition, although normalisation of lipid profiles using 
cholestyramine or HMG-CoA reductase inhibitors has been reported (Leone et al 
1991; McCoy and Yokoyama 1991).  Normalisation of the lipid profile does not 
necessarily prevent progression to hepatic failure in CESD, however, as seen in the 
case reported by Leone et al (1995).  Enzyme replacement therapy has shown 
promise in reducing lipid deposition in peripheral tissues in mouse and rat models of 
complete LAL deficiency analogous to Wolman’s disease, and is now being 
examined in phase I/II clinical trials for patients with CESD (Du et al 2008; Enns 
2012).  Although this is not currently routine treatment and is unlikely to be of 
significant benefit once irreversible liver damage has occurred this is an important 
research area, as is detection of CESD in adults with abnormal liver function. 
 
Although successful liver transplantation for CESD has previously been reported in 
children and young adolescents (Arterburn et al 1991; Ferry et al 1991; Leone et al 
1995), this patient is far older than any of the previously reported cases. As a result 
of the increased cardiovascular mortality seen in CESD, and given that the patient 
had been untreated for the vast majority of her life, a major concern was the degree 
  
of established atherosclerosis and associated cardiovascular risk present. Although 
our patient had no overt signs of vascular disease, CT imaging had revealed 
extensive aortic calcification (Figure 1). Furthermore, doppler ultrasound imaging of 
the carotid arteries revealed dense plaques associated with mild stenoses.  These 
findings of established atherosclerosis would be in keeping with her known CESD 
and may have been a factor in the development of post-transplant hepatic artery 
thrombosis; arterial anastomosis is technically more challenging in the presence of 
calcified atherosclerotic plaques and plaque rupture around the site of anastomosis 
can occur.  Despite these findings, we felt that there remained a clear benefit for liver 
transplantation.  
 
Initial fasting lipid profiling demonstrated hypercholesterolemia with low HDL 
cholesterol (Table 1). Although statin therapy led to a reduction in total cholesterol, 
the low HDL cholesterol reversed only following liver transplantation. Multiple studies 
in healthy subjects have demonstrated the predictive importance of low HDL 
cholesterol in future cardiac and cerebrovascular outcome (Natarajan et al 2010). 
Indeed a recent consensus statement on defining the metabolic syndrome has used 
a cut-off of less than 1.3 mmol/L as abnormal in a female population (Alberti et al 
2009). Normalisation of HDL cholesterol levels in CESD following commencement of 
HMG-CoA reductase inhibitors has previously been reported in pre-cirrhotic cases in 
the paediatric population (Leone et al 1991), so it is likely that the low HDL 
cholesterol level observed here was related to impaired liver synthetic function. Liver 
transplantation may therefore be effective in reducing long-term vascular risk 
although this may be counter-balanced by the side-effects of calcineurin inhibitors 
  
and the ongoing peripheral defect as evidenced by persistent leukocyte acid 
esterase deficiency. 
 
In summary, we present the first published case of successful liver transplantation in 
an adult with CESD. The report highlights the challenges of concomitant vascular 
disease and the potential indolent nature of CESD in adulthood.  The patient 
described here was lost to follow up twice before presenting with severe 
decompensated liver disease.  Our case therefore also emphasises the need for 
educating patients with asymptomatic but potentially progressive liver disease and 
for continued awareness amongst clinicians overseeing adult metabolic disorders. 
Two years following transplantation, the patient has remained free of vascular 
events, with excellent liver function and a normal lipid profile. Liver transplantation for 
CESD may therefore yield a significant survival advantage even well into adulthood. 
There is little evidence to support liver replacement other than in the context of liver 
failure. We can only speculate as to whether pre-emptive liver transplantation might 
ameliorate the mortality associated with vascular disease in CESD, particularly if 
HMG-CoA reductase inhibition might already offset this. Liver transplantation is 
therefore a viable option for adults with liver failure related to CESD; close 
monitoring of patients with CESD and liaison with tertiary hepatology services are 
important for the optimal timing of this intervention. 
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Figure legends 
Figure 1.  CT images of a 42 year-old woman with end-stage liver disease due to CESD.  
Imaging obtained prior to liver transplantation. Post-contrast axial CT image of the upper 
abdomen showing a nodular liver containing multiple tiny foci of calcification in association 
with splenomegaly, ascites and a moderate right pleural effusion (A). Non-contrast sagittal 
CT images of the major arteries showing extensive calcification in the abdominal and 
thoracic aorta (B and C respectively). 
 
Figure 2.  Liver explant histology following transplantation for end-stage liver disease due to 
CESD.  Chromotrope Aniline Blue staining (A) demonstrating established cirrhosis with 
complete nodules surrounded by broad fibrous septae (x40).  Haematoxylin and Eosin 
(H&E) stained section (B) demonstrating numerous foamy macrophages with tan-coloured 
cytoplasm within residual portal areas and fibrous septae (x200).  H&E stained section (C) 
demonstrating lipid laden, foamy hypertrophic Kupffer cells and sinusoidal macrophages 
(arrow) (x400).  CD68 staining (D) showing strong positivity for intrasinusoidal macrophages 
and Kupffer cells (x400) which are periodic acid Schiff positive and diastase resistant (E) 
(x400).  
 
Figure 3.  DNA sequence chromatograms of a section of the LIPA gene from a 42 year-old 
woman with CESD.  The grey boxes highlight heterozygous substitutions found in both 
forward and reverse directions at locations 599 (top, C substituted for wild-type T) and 894 
(bottom, A substituted for wild-type G).  The former is thought to result in disruption of alpha-
helical structure, while the latter is found at a splice junction and usually causes deletion of 
exon 8, resulting in less than 10% expression of normal protein (r.[894g>t,822_894delinsu]). 
